What were the key takeaways from Rapid Micro's earnings call?

What factors drove the changes in Rapid Micro's revenue and profit?

What is Rapid Micro's latest dividend and current dividend yield?

What guidance did Rapid Micro's management provide for the next earnings period?

What does Rapid Micro do and what are its main business segments?

What is the revenue and EPS growth rate for Rapid Micro year over year?

Did Rapid Micro beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Rapid Micro next quarter?

- **Record Q4 Growth**: $11.3M revenue (37% YoY), 16 system placements, and 190 total systems highlight strong commercial execution.
- **Strategic Wins**: Samsung expands deployment, Amgen deploys globally, and MilliporeSigma collaboration drives 2026 placements.
- **Gross Margin Recovery**: 2026 target of 20% gross margin, driven by consumable cost reductions and service margin expansion.
- **Innovation**: Cloud-native software platform to launch in H2 2026, enabling AI-driven analytics and recurring revenue opportunities.
- **Financial Discipline**: $39M cash balance, prudent debt management, and 2026 guidance reflecting cautious yet achievable growth targets.

**【Management Opening Remarks】**
- Presented Q4 2025 financial results and highlighted forward-looking statements, including risks related to macroeconomic conditions, customer adoption, and debt obligations.
- Emphasized non-GAAP financial measures and provided reconciliations for investors.

**【CEO Summary Section】**
- **Q4 Revenue Performance**: $11.3 million (37% YoY growth), driven by 16 system placements and 190 total systems globally.
- **Key Wins**: Samsung Biologics expanded deployment with a multisystem order; Amgen placed systems across North America, Europe, and Asia.
- **Consumable Growth**: 17% YoY increase, with recurring revenue accounting for 53% of total revenue, reflecting strong customer utilization.
- **Gross Margin Challenges**: Q4 gross margin negative 3% due to $1.1 million inventory write-off, but expects 20% full-year 2026 gross margin with Q4 exit rate >20%.
- **Strategic Initiatives**: Launch of cloud-native software platform in H2 2026 to enhance AI-driven analytics and customer insights.
- **2026 Outlook**: Guidance of $37-41 million revenue with 30-38 system placements, focusing on cost reductions and service margin improvements.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net loss of $12.5 million (including $1.1M inventory charge), cash balance of $39 million, and $25M undrawn debt facility.
- **Revenue Breakdown**: Product revenue $9.3M (78% YoY), service revenue $2M, recurring revenue $4.6M (10% YoY).
- **Gross Margin Details**: Product margin -8% (excluding charge, +4%), service margin 22%.
- **2026 Guidance**: Operating expenses $47-51M, non-cash expenses $10M, CapEx $2M, interest expense $2M.
- **Margin Expectations**: Q1 2026 gross margin mid-single digits, improving to 20%+ by year-end with consumables turning positive in H2.

**【Q&A Highlights】**
- **Validation Timelines**: Samsung and Amgen systems expected to validate in 2026, with CDMO adoption growing alongside principal manufacturers.
- **Gross Margin Confidence**: 2026 target of 20% driven by consumable cost reductions (locked-in with suppliers) and service margin recovery.
- **Customer Segments**: CDMOs (e.g., Lonza, Samsung) and principal manufacturers (e.g., Amgen) both strong contributors, with CDMO growth accelerating.
- **Software Platform**: Cloud-native solution to monetize global data through predictive analytics and AI, with first customer pilot in progress.
- **Inventory Management**: No further write-offs expected in 2026; manufacturing improvements reducing product costs.


Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue of $7.8 million, with 40% year-over-year increase in consumables.
- **Multi-System Win**: Record deal for double-digit placements across 3 geographies, raising 2025 guidance to $33M+.
- **Gross Margin Expansion**: 9% in Q3, with product margins turning positive in Q4 and 2026 improvements expected.
- **MilliporeSigma Collaboration**: Supply agreement nearing completion, targeting 2026 margin benefits.
- **Onshoring Opportunity**: Potential 2026 growth from U.S. pharma manufacturing investments.

**【CEO Summary Section】**
- **Q3 2025 Revenue**: $7.8 million, above midpoint of guidance, with 40% year-over-year growth in consumables revenue.
- **Gross Margin**: 9%, up 70 basis points year-over-year, with service margins at 40%.
- **Multi-System Order**: Record deal with a top 20 global biopharma customer for deployment across North America, Europe, and Asia Pacific, contributing to 27+ system placements in 2025.
- **MilliporeSigma Collaboration**: Initial product supply agreement nearing completion, with validation studies underway to lower direct product costs and improve margins starting in 2026.
- **2025 Guidance Update**: Total revenue raised to at least $33 million, including 27+ system placements.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Product revenue ($5.2M), service revenue ($2.6M), and recurring revenue ($4.8M) up 32% year-over-year.
- **Gross Margin**: 9% for Q3, with product margins expected to turn positive in Q4 and service margins stepping down temporarily.
- **Operating Expenses**: $12.1 million, down 5% year-over-year, with full-year OpEx guidance of $48 million.
- **Cash Position**: $42 million at quarter-end, with $40 million expected by year-end.
- **2026 Outlook**: Gross margin improvement driven by product cost reductions, manufacturing efficiency, and MilliporeSigma collaboration benefits.

**【Q&A Key Highlights】**
- **Order Size and Timing**: Multi-system order includes double-digit placements, with initial contributions in Q4 and full ramp-up in 2026.
- **Geographic Demand**: Broad-based adoption across North America, Europe, and Asia Pacific, with no single region dominating.
- **MilliporeSigma Progress**: Supply agreement validation studies ongoing, with financial benefits expected in 2H 2026.
- **Onshoring Impact**: Potential 2026 tailwind for U.S. manufacturing projects, though timing and scale remain uncertain.
- **Pipeline Strength**: Multiple multi-system orders in funnel, driven by ROI and global standardization needs.

Rapid Micro Biosystems, Inc. (RPID) Q3 2025 Earnings Call Transcript

- **$45M Term Loan Secures Liquidity**: $20M drawn in Q2, supporting cash flow and strategic initiatives.
- **Revenue Growth Resilient**: Q2 revenue $7.3M (+10% YoY), with 15% recurring revenue growth.
- **Gross Margin Expansion**: 4% in Q2 (up 7pts YoY), with sequential improvement in product margins.
- **MilliporeSigma Partnership**: Joint innovation and commercialization efforts driving long-term growth.
- **2026 Outlook**: U.S. pharma build-outs and automation adoption to fuel system placements and gross margin expansion.

**【Management Opening Remarks】**
- Announced a new $45 million 5-year term loan facility with Trinity Capital, with $20 million drawn in Q2, supporting cash flow and strategic execution.
- Q2 2025 revenue of $7.3 million (+10% YoY), driven by 15% growth in recurring revenue (consumables and services).
- 4 Growth Direct Systems placed, within guidance of 21-25 for the year, and 169 cumulative systems globally.
- Gross margin improved to 4% (up 7pts YoY), with sequential progress in product and service margins.

**【CEO Commentary】**
- Highlighted the MilliporeSigma partnership, with training sessions conducted across regions and joint innovation initiatives underway.
- Noted 15% recurring revenue growth and 18% service revenue growth, reflecting strong customer engagement.
- Discussed macro trends, including U.S. pharmaceutical manufacturing build-out and automation adoption, positioning Growth Direct as a key solution.
- Outlined 2026 drivers: robust sales funnel, MilliporeSigma contributions, and gross margin expansion through cost reduction and efficiency.
- Upcoming events include PDA Micro Conference, PharmaLab Congress, and Daiichi Sankyo-hosted Growth Direct Day in Germany.

**【CFO Financial Commentary】**
- Q2 2025 financials: $7.3 million revenue (+10% YoY), $4.4 million recurring revenue (+15%), and $2.8 million non-recurring revenue.
- Gross margin of 4% (4% product, 32% service), with sequential improvement in product margins.
- Operating expenses down 6% YoY to $12.4 million, driven by cost control and efficiency programs.
- Full-year 2025 guidance reaffirmed: ≥$32 million revenue, high single to low teens gross margin, and $46-48 million OpEx.
- Cash position of $32 million at end of Q2, with $40 million expected by year-end.

**【Q&A Highlights】**
- **Pharma Industry Dynamics**: CEO noted mixed timing uncertainty but high ROI projects like Growth Direct proceeding, with U.S. manufacturing build-outs driving automation adoption.
- **CAR-T and New Builds**: 70% of placements in existing facilities, but new builds in high-cost regions (e.g., U.S.) favor advanced automation.
- **System Placements**: Guidance adjusted to low end of 21-25 due to trade dynamics, but 4-6 placements expected in Q3.
- **Consumables Growth**: Sequential increases in Q3 and Q4 driven by new high-volume sites.
- **Gross Margin Levers**: Product cost reduction, manufacturing efficiency, and MilliporeSigma collaboration targeting 2026 improvements.
- **Onshoring Impact**: Potential mid-2026 tailwinds from U.S. manufacturing expansion and automation adoption.

Rapid Micro Biosystems, Inc. (RPID) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 28% to $7.2M, driven by 64% service revenue surge.
- **Gross Margin Transformation**: 33ppt improvement to 6%, with service margins at 43%.
- **Cost Efficiency**: Operating expenses down 5%, cash burn expected to halve to $30M.
- **Market Momentum**: 165 systems placed, multi-site deployments underway, U.S. pharma buildouts driving demand.
- **Strategic Wins**: MilliporeSigma collaboration on track for cost savings, AI integration in R&D pipeline.
- **Tariff Resilience**: Minimal impact due to domestic sourcing and USMCA exemptions.

**【CFO Financial Summary】**
- Q1 2025 revenue reached $7.2 million, up 28% YoY, driven by 64% service revenue growth and 10% product revenue increase.
- Gross margin improved 33ppt to 6%, with service margins at 43% vs. -3% last year.
- Operating expenses decreased 5% to $12.1 million, benefiting from cost-cutting initiatives.
- Cash balance remained strong at $42 million, with full-year cash burn expected to halve to $30 million.

**【Customer & Market Insights】**
- 165 cumulative system placements (146 validated), with multi-system deployments in pipeline.
- Service revenue hit $3.1 million Q1, highest on record, due to validation activity and contracts.
- Tariff impact minimal; 80%+ materials sourced domestically or via USMCA-exempt Canadian plastics.

**【Strategic Initiatives】**
- MilliporeSigma collaboration advancing: joint teams working on cost synergies and supply chain efficiency.
- AI integration in R&D pipeline to enhance data analytics for Growth Direct systems.
- Targeting $32+ million 2025 revenue with 21-25 system placements, guided by expanding pharma manufacturing in the U.S.

**【Q&A Highlights】**
- Customers prioritizing high-ROI projects; Growth Direct seen as critical for new facility builds.
- Gross margin exit rate for 2025 expected to exceed high-single digits, potentially into low-teens.
- Validation activity on track for 18+ completions, up from 16 in 2024.
- MilliporeSigma collaboration could unlock cost savings in consumables sourcing by year-end.

Rapid Micro Biosystems (RPID)-9 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Q4 2024 revenue up 30% YoY to $8.2M, driven by 6 system placements and 27% recurring revenue growth. 
- **Gross Margin Turnaround**: Q4 gross margin improved to 12% (vs. -3% Q4 2023), with 2025 target of 7-15%. 
- **MilliporeSigma Deal**: 5-year partnership to expand into adjacents, with system purchases weighted for 2026+ impact. 
- **Lonza Blueprint**: End-to-end automation success at Lonza positions Rapid Micro as industry standard for pharma QC.

**【CEO Key Highlights】**
- **Q4 2024 Financial Performance**: Total revenue of $8.2M (+30% YoY), recurring revenue $4.2M (+27% YoY), 6 Growth Direct systems placed (total 21 in 2024), and 162 cumulative systems globally. Gross margin improved to 12% (vs. -3% Q4 2023). 
- **MilliporeSigma Collaboration**: 5-year global co-exclusive distribution agreement with minimum system purchases weighted towards 2026. Focus on adjacent markets (e.g., personal care, medical devices) and supply chain efficiencies to drive gross margin improvement. 
- **2025 Priorities**: Accelerate system placements (21-25 units), improve gross margins (high single to low teens), and leverage Lonza's end-to-end automation as a customer blueprint. 

**【CFO Financial Breakdown】**
- **Q4 2024 Results**: Product margin -8% (vs. -14% Q4 2023), service margin 47% (vs. 19% Q4 2023), total gross margin 12% (vs. -3% Q4 2023). Operating expenses down 7% to $11.2M, driven by cost control. 
- **2025 Outlook**: Revenue $32M+, 21-25 system placements, gross margin 7-15%, and cash burn $30M (vs. $44M in 2024). 

**【Q&A Key Takeaways】**
- **Market Expansion**: MilliporeSigma will target non-pharma adjacents (e.g., cosmetics, medical devices), while Rapid Micro maintains direct pharma sales. 
- **System Sales**: 2025 guide excludes MilliporeSigma contributions but includes potential upside from large multisystem orders. 
- **Lonza Impact**: End-to-end automation success may replicate across customers, with Lonza planning further deployments. 
- **AI Integration**: Exploring AI opportunities for data insights, though no concrete plans yet.

Actual	-20.01	-0.71	-0.35	-0.35	-0.31	-0.38	-0.39	-0.32	-0.33	-0.31	-0.26	-0.31	-0.29	-0.26	-0.22	-0.26	-0.27	-0.26	-0.28
Forecast	-1.0914	-0.3875	-0.28	-0.3357	-0.3175	-0.3667	-0.36	-0.365	-0.34	-0.3067	-0.3	-0.29	-0.2767	-0.255	-0.23	-0.27	-0.2533	-0.245	-0.2267
Surprise	-1733.43%	-83.23%	-25.00%	-4.26%	+2.36%	-3.63%	-8.33%	+12.33%	+2.94%	-1.08%	+13.33%	-6.90%	-4.81%	-1.96%	+4.35%	+3.70%	-6.59%	-6.12%	-23.51%

RPID

RPID fundamentals

RPID Q4 2025 Earnings

Earnings Call

You can ask Aime

RPID

RPID fundamentals

RPID Q4 2025 Earnings

Earnings Call

RPID Earnings Call Summary for Q4/20258:30 AM on Mar 12, 2026

RPID Earnings Call Summary for Q3/20258:30 AM on Nov 7, 2025

RPID Earnings Call Summary for Q2/20258:30 AM on Aug 12, 2025

RPID Earnings Call Summary for Q1/20258:30 AM on May 9, 2025

RPID Earnings Call Summary for Q4/20248:00 AM on Feb 28, 2025

You can ask Aime